A bitter melon natural compound ameliorates the myotonic dystrophy type 1 skeletal muscle phenotype in a sex-specific manner
Results indicate that sustained AMPK activation with BMC-25 confers multifaceted benefits to DM1 skeletal muscle by improving core DM1 pathogenic features in a sex-dependent manner, and highlights the potential of natural compounds like BMCs as novel, promising and accessible therapeutics for the DM1 muscle pathology.